Cipher Pharmaceuticals (TSE:CPH) Share Price Passes Above 50 Day Moving Average of $8.28

Cipher Pharmaceuticals Inc. (TSE:CPH) (NASDAQ:CPHR) shares passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of C$8.28 and traded as high as C$9.03. Cipher Pharmaceuticals shares last traded at C$8.95, with a volume of 26,194 shares traded.

Analysts Set New Price Targets

Separately, Citigroup raised their price objective on Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th.

Cipher Pharmaceuticals Price Performance

The stock’s 50-day moving average is C$8.28 and its 200 day moving average is C$6.67. The company has a debt-to-equity ratio of 0.44, a current ratio of 9.19 and a quick ratio of 2.67. The company has a market cap of C$214.71 million, a PE ratio of 8.21 and a beta of 0.97.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last posted its quarterly earnings data on Thursday, March 14th. The company reported C$0.41 earnings per share for the quarter, topping analysts’ consensus estimates of C$0.15 by C$0.26. Cipher Pharmaceuticals had a return on equity of 28.19% and a net margin of 96.32%. The firm had revenue of C$6.70 million during the quarter, compared to analysts’ expectations of C$7.31 million. On average, equities analysts anticipate that Cipher Pharmaceuticals Inc. will post 0.6040609 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.